Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma

H. Lee Moffitt Cancer Center and Research Institute

Status: Enrolling

Conditions: Small Lymphocytic Lymphoma (SLL); Chronic Lymphocytic Leukemia (CLL)

Treatments: Drug: Bruton's tyrosine kinase inhibitor; Drug: B-Cell Lymphoma 2 Protein Inhibitor

Study type: Observational

Funder types: Other; NETWORK; Industry

Identifiers

NCT07030400

MCC-23558

Details and patient eligibility

About

The study aims to improve our understanding of how quality of life, fatigue, and symptoms change over 2 years when participants are treated for chronic lymphocytic leukemia or small lymphocytic lymphoma. We will compare two types of treatment to help future patients with chronic lymphocytic leukemia or small lymphocytic lymphoma know what to anticipate.

Enrollment: 100 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All patients with pathology-confirmed diagnoses of CLL who are within seven days of starting treatment with a BTKi +/- an anti-CD 20 monoclonal antibody or BCL2i with Obinutuzumab treatment will be included.
• Subjects must be able to read and speak English or Spanish at the 8th grade level.

Exclusion criteria

• Patients with dementia, traumatic brain injury, or individuals with central nervous system involvement of their leukemia will be excluded from study participation.

Trial design

100 participants in 2 patient groups

Bruton's tyrosine kinase inhibitor treatment

Description:

Patients treated with a Bruton's tyrosine kinase inhibitor.

Treatment:

Drug: Bruton's tyrosine kinase inhibitor

B-Cell Lymphoma 2 Protein Inhibitor treatment

Description:

Patients treated with a B-Cell Lymphoma 2 Protein Inhibitor.

Treatment:

Drug: B-Cell Lymphoma 2 Protein Inhibitor